Investor Presentaiton

Investment Highlights ONENESS Leading Biotech Value-added strategy Strong financial standing Largest biotech company in Taiwan in terms of market cap (US$ 3.4bn) Has completed US$ 530 mn licensing deal for the atopic dermatitis new drug FB-825, the largest in Taiwan biotech history Developing First-in-Class and Best-in-Class new drug for massive unmet needs Each pipeline under development of multiple indications to maximize the value of the assets and mitigate the risk of development Sufficient cash to support upcoming development of new drugs. Anticipated profitability from the launch of Fespixon® and the licensing of new drugs | 5

View entire presentation